NIAMS Offers SBIR Funds for Multiplex Dx

Apr 06, 2009

NEW YORK (GenomeWeb News) – The National Institute of Arthritis and Musculoskeletal and Skin Diseases plans to fund $100,000 for phase I and $750,000 for phase II Small Business Innovation Research grants to companies seeking to develop multiplex diagnostic tests that could apply to a variety of diseases.

NIAMS wants to fund projects that will develop multiplex assay methodologies for candidate biomarkers for musculoskeletal, rheumatic, and skin diseases.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

What You Might Learn

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

From Whales to Urchins to Algae

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

In the Skin

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

This Week in PNAS

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Featured White Papers

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Main menu